SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a cl...
* Development of Leptin receptor-based technology and hybrid LNP platform * Combining Blood-Brai...
* ImmunoForge's LMT15 Platform combines high BBB permeability with proprietary long-acting ELP t...
* Conducting global licensing partnering of LMT15, a proprietary BBB Shuttle platform * Also di...
* Focusing on global out-licensing of Phase 2 assets PF1801 and PF1804. * Company to engage with...
SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approv...